articleNature MedicineJan 23, 2023Closed access

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

SMSham MailankodyJMJeffrey MatousSCSaurabh ChhabraMLMichaela LiedtkeSSSurbhi Sidana

Memorial Sloan Kettering Cancer Center · Cornell University · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

236
total citations
FWCI
50.92
Percentile
100%
References
31
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Medicine
  • Fludarabine
  • Cytokine release syndrome
  • Cyclophosphamide
  • Regimen
  • Adverse effect
  • Tolerability
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.